After rigorous peer review, the Michael Smith Foundation for Health Research (MSFHR) recently awarded the Fraser Health Authority team in British Columbia (BC), a three-year project team grant worth $500,000. […]

Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

Contributors: Dr. Adrian Lau, Dr. Claudia Gagnon, Dr. Laëtitia Michou, Dr. Emma Billington, Dr. Zahra Bardai, Dr. Dr. Vithika Sivabalasundaram, Dr. Rowena Ridout, Dr. Sandra Kim, Dr. Suzanne Morin Recommendations […]

Living with osteoporosis is a unique journey for each of us. For those with mild osteoporosis there may be little impact on how you live – while for others with […]